Hierarchical Negative Sampling Based Graph Contrastive Learning Approach for Drug-Disease Association Prediction
- 31 January 2024
- journal article
- research article
- Published by Institute of Electrical and Electronics Engineers (IEEE) in IEEE Journal of Biomedical and Health Informatics
- Vol. 28 (5) , 3146-3157
Abstract
Predicting potential drug-disease associations (RDAs) plays a pivotal role in elucidating therapeutic strategies for diseases and facilitating drug repositioning, making it of paramount importance. However, existing methods are constrained and rely heavily on limited domain-specific knowledge, impeding their ability to effectively predict candidate associations between drugs and diseases. Moreover, the simplistic definition of unknown information pertaining to drug-disease relationships as negative samples presents inherent limitations. To overcome these challenges, we introduce a novel hierarchical negative sampling-based graph contrastive model, termed HSGCLRDA, which aims to forecast latent associations between drugs and diseases. In this study, HSGCLRDA integrates the association information as well as similarity between drugs, diseases and proteins. Meanwhile, the model constructs a drug-disease-protein heterogeneous network. Subsequently, employing a hierarchical structural sampling technique, we establish reliable negative drug-disease samples utilizing PageRank algorithms. Utilizing meta-path aggregation within the heterogeneous network, we derive low-dimensional representations for drugs and diseases, thereby constructing global and local feature graphs that capture their interactions comprehensively. To obtain representation information, we adopt a self-supervised graph contrastive approach that leverages graph convolutional networks (GCNs) and second-order GCNs to extract feature graph information. Furthermore, we integrate a contrastive cost function derived from the cross-entropy cost function, facilitating holistic model optimization. Experimental results obtained from benchmark datasets not only showcase the superior performance of HSGCLRDA compared to various baseline methods in predicting RDAs but also emphasize its practical utility in identifying novel potential diseases associated with existing drugs through meticulous case studies.Keywords
Funding Information
- Scientific Research Fund Project of the Education Department of Liaoning Province (LJKZ0028)
- 2023 Liaoning Provincial Natural Science Foundation Program Project (2023-MS-130)
This publication has 44 references indexed in Scilit:
- REDDA: Integrating multiple biological relations to heterogeneous graph neural network for drug-disease association predictionComputers in Biology and Medicine, 2022
- Drug–disease associations prediction via Multiple Kernel-based Dual Graph Regularized Least SquaresApplied Soft Computing, 2021
- Levonorgestrel intrauterine system (IUS) in a patient with uterine didelphys: A case reportContraception, 2020
- iPiDA-sHN: Identification of Piwi-interacting RNA-disease associations by selecting high quality negative samplesComputational Biology and Chemistry, 2020
- Predicting post one-year durability of glucose-lowering monotherapies in patients with newly-diagnosed type 2 diabetes mellitus – A MASTERMIND precision medicine approach (UKPDS 87)Diabetes Research and Clinical Practice, 2020
- A real-world study in patients with type 2 diabetes mellitus treated with gliclazide modified-release during fasting: DIA-RAMADANDiabetes Research and Clinical Practice, 2020
- Graph neural networks: A review of methods and applicationsAI Open, 2020
- Advancing Drug Discovery via Artificial IntelligenceTrends in Pharmacological Sciences, 2019
- Clinical and molecular characterization of a novel INS mutation identified in patients with MODY phenotypeEuropean Journal of Medical Genetics, 2016
- Epilepsy phenotypes in siblings with Norrie diseaseBrain and Development, 2015